Late stage drug for ovarian cancer by Amgen Inc fails to improve overall survival rate, reveals study
Trebananib, the experimental last stage platinum-resistant ovarian cancer drug by Amgen, fails to improve overall survival (OS) rate very significantly, it was revealed earlier today. Patient on whom this new d...